Adaptive Biotechnologies (ADPT) net assets (shareholders' equity)

Net assets · fiscal 2025
$218.79M

Adaptive Biotechnologies (ADPT) had net assets of $218.79M at the end of fiscal 2025 (December 31, 2025). That is 7.9% higher than the $202.71M of fiscal 2024. Figures as of 19 Nov 2026, 03:24 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Net assets, fiscal 2025
$218.79M
Change on fiscal 2024
+7.9%
Growth, 5 years
−21.7% a year
Highest on record
$743.27Mfiscal 2020
Lowest on record
-$258.11Mfiscal 2018
Fiscal years on record
92017–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Adaptive Biotechnologies net assets (shareholders' equity), in more detail

Over the five fiscal years to 2025 net assets shrank at a compound 21.7% a year. Across the 9 fiscal years on record (2017–2025), the highest was $743.27M in fiscal 2020 and the lowest -$258.11M in fiscal 2018.

History · 9 fiscal years

Net assets by fiscal year

Adaptive Biotechnologies net assets (shareholders' equity), year by year

Adaptive Biotechnologies (ADPT) net assets (shareholders' equity) by fiscal year
Fiscal yearNet assetsChangeYear ended
2025$218.79M 7.9% up
2024$202.71M 34.3% down
2023$308.40M 33.6% down
2022$464.17M 23.2% down
2021$603.99M 18.7% down
2020$743.27M 30.2% up
2019$571.04M—
2018-$258.11M—
2017-$224.62M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value.

How to read it

Large buybacks and write-offs shrink it without the business getting worse, so a falling or negative figure needs the reason before a verdict.

Net assets at health care companies of similar size

Net assets of Adaptive Biotechnologies and comparable companies
CompanyNet assetsFiscal year
Dianthus Therapeutics DNTH$493.40M2025
MiniMed Group MMED$3.61B2026
Adaptive Biotechnologies ADPT$218.79M2025
Heartflow HTFL$300.65M2025
CRISPR Therapeutics CRSP$1.92B2025
Travere Therapeutics TVTX$114.83M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on ADPT

Adaptive Biotechnologies, figure by figure

Adaptive Biotechnologies (ADPT) overview: price, valuation and scorecardAll health care companies by market value

Adaptive Biotechnologies net assets (shareholders' equity): questions and answers

What are Adaptive Biotechnologies's net assets?

Adaptive Biotechnologies (ADPT) had net assets of $218.79M at the end of fiscal 2025 (December 31, 2025). That is 7.9% higher than the $202.71M of fiscal 2024.

What is the growth rate of Adaptive Biotechnologies's net assets?

Over the five fiscal years to 2025 net assets shrank at a compound 21.7% a year.

What are the highest and lowest net assets figures on record for Adaptive Biotechnologies?

Across the 9 fiscal years on record (2017–2025), the highest was $743.27M in fiscal 2020 and the lowest -$258.11M in fiscal 2018.

How is Adaptive Biotechnologies's net assets calculated?

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value. For Adaptive Biotechnologies it is on record here for 9 fiscal years, 2017 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Adaptive Biotechnologies (ADPT) net assets (shareholders' equity)”, data as of 19 November 2026. https://funkfolio.com/stock/ADPT/net-assets

Underlying data: the company's filings with the SEC and Yahoo Finance.